i-SENS, Inc. Stock

Equities

A099190

KR7099190001

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
19,630 KRW -1.85% Intraday chart for i-SENS, Inc. +4.64% -31.36%

Financials

Sales 2024 * 324B 235M 323M Sales 2025 * 392B 285M 390M Capitalization 540B 393M 538M
Net income 2024 * 29B 21.08M 28.88M Net income 2025 * 44B 31.99M 43.82M EV / Sales 2024 * 1.95 x
Net Debt 2024 * 92B 66.88M 91.63M Net Debt 2025 * 119B 86.51M 119M EV / Sales 2025 * 1.68 x
P/E ratio 2024 *
18.2 x
P/E ratio 2025 *
12.3 x
Employees 794
Yield 2024 *
0.9%
Yield 2025 *
0.9%
Free-Float 63.73%
More Fundamentals * Assessed data
Dynamic Chart
I-SENS, Inc. announced that it has received KRW 50 billion in funding from NH Investment & Securities Co., Ltd., Atinum Investment Co., Ltd CI
I-SENS, Inc. announced that it expects to receive KRW 50 billion in funding from NH Investment & Securities Co., Ltd., Atinum Investment Co., Ltd CI
I-SENS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
I-SENS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
I-SENS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
I-SENS, Inc. completed the acquisition of AgaMatrix, Inc. CI
I-SENS, Inc. agreed to acquire AgaMatrix, Inc. for $20 million. CI
I-SENS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
I-SENS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
I-SENS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
I-SENS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
I-SENS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
I-SENS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
I-SENS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Tranche Update on i-SENS, Inc.'s Equity Buyback Plan announced on August 20, 2018. CI
More news
1 day-1.85%
1 week+4.64%
Current month-4.48%
1 month-4.48%
3 months-24.64%
6 months-13.33%
Current year-31.36%
More quotes
1 week
18 990.00
Extreme 18990
20 400.00
1 month
17 910.00
Extreme 17910
21 500.00
Current year
17 910.00
Extreme 17910
30 400.00
1 year
14 800.00
Extreme 14800
39 700.00
3 years
12 900.00
Extreme 12900
39 700.00
5 years
7 500.00
Extreme 7500
39 700.00
10 years
7 500.00
Extreme 7500
39 700.00
More quotes
Managers TitleAgeSince
Founder 64 00-05-03
Founder 70 00-05-03
Chief Tech/Sci/R&D Officer 58 -
Members of the board TitleAgeSince
Founder 70 00-05-03
Founder 64 00-05-03
Director/Board Member 51 -
More insiders
Date Price Change Volume
24-04-30 19,630 -1.85% 129,899
24-04-29 20,000 +4.60% 374,080
24-04-26 19,120 +0.31% 101,132
24-04-25 19,060 -0.42% 50,624
24-04-24 19,140 -1.75% 138,879

End-of-day quote Korea S.E., April 29, 2024

More quotes
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Company’s products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others; electrolyte analyzers and cartridges; immunosensors, as well as other related accessories, such as connectors, lancets, blood glucose data management software and lancing devices, among others. The Company distributes its products within domestic market and to overseas markets including Japan, Europe, the United States and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
19,630 KRW
Average target price
31,750 KRW
Spread / Average Target
+61.74%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A099190 Stock